 The study estimated that using quadrivalent influenza vaccines, QIV, instead of annual trivalent influenza vaccines, TIV, would have reduced societal costs and healthcare burden in Brazil, Colombia, and Panama by up to US$33,700 per 100,000-person years. This article was authored by Aurelian Jamot, Emily Clay, Berenjie Macabio, and others.